Arvinas, Inc. (ARVN) AI Stock Analysis
ARVN AI stock analysis summary
AI ResearchArvinas, Inc. (ARVN) is a clinical-stage biotechnology company developing targeted protein degraders using its PROTAC platform. Over the trailing twelve months ended June 30, 2026, the company generated revenue of $316.7M and an EPS of $0.26. The balance sheet holds $559.7M in net cash, though the stock has declined 41.2% year-to-date.
- Market cap
- $449.7M
- Revenue (TTM)
- $316.7M
- P/E
- 26.8x fwd 17.9x
- 1Y return
- -28.0% S&P 500 16.8%
- Avg. target
- $13.93 99.8% vs last close
Bull case
- Arvinas maintained a net cash position of $559.7M as of June 30, 2026, supported by a current ratio of 7.91.
- Trailing twelve-month revenue reached $316.7M, supported by 1014.7% year-over-year revenue growth in the quarter ended June 30, 2026.
- The analyst mean price target of $13.93 represents a 99.8% premium over the last close of $6.97.
Bear case
- Free cash flow was -$275.7M in FY2025 following negative free cash flow of -$261.1M in FY2024.
- Consensus estimates for next fiscal year project revenue to fall 78.3% to $64.2M, with EPS projected at -$3.23.
- Shares have dropped 91.8% over the past 5 years and closed 29.6% below their 200-day moving average.
What Arvinas does
Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies that degrade disease-causing proteins. Its core capability centers on proteolysis targeting chimeras (PROTAC), which utilize natural cellular mechanisms to remove harmful proteins. Its pipeline includes investigational oral therapies such as Bavdegalutamide and ARV-766, which are in Phase 1/2 clinical trials for metastatic castration-resistant prostate cancer. The company is also evaluating ARV-471 in Phase 3 trials for estrogen receptor-positive/HER2-negative breast cancer. Arvinas collaborates with pharmaceutical partners including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.
Growth and profitability
Revenue increased from $46.7M in FY2021 to $262.6M in FY2025, recording a 5-year revenue CAGR of 64.5%. Annual net results remained negative over this period, improving from -$183.2M in FY2021 and -$367.3M in FY2023 to -$80.8M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 1014.7% year-over-year. For the trailing twelve months, revenue reached $316.7M with an operating margin of 66.4% and net income yielding an EPS of $0.26. For FY2025, R&D expenses were $282.9M, down from $348.2M in FY2024.
Balance sheet and cash flow
As of June 30, 2026, Arvinas held $567.9M in cash and short-term investments against $8.2M in total debt, resulting in net cash of $559.7M. The current ratio stood at 7.91 and debt-to-equity was 0.01. Free cash flow was -$275.7M in FY2025, with operating cash flow at -$273.8M. Capital expenditures were $1.9M in FY2025, and the company allocated $91.9M to share buybacks during the year.
Valuation and performance
At a share price of $6.97, Arvinas has a market capitalization of $449.7M and an enterprise value of -$48.6M. Its trailing P/E of 26.8x compares to 24.6x for the median of its US-listed Healthcare peers, while its forward P/E is 17.9x versus the peer median of 17.3x. The stock trades at 1.4x sales, below the peer median of 4.1x. Over the past year, ARVN fell 28.0%, while the S&P 500 (SPY) returned 16.8%.
What analysts expect
Wall Street coverage includes 5 Strong Buy, 2 Buy, 8 Hold, 0 Sell, and 1 Strong Sell recommendations. The mean price target is $13.93, which is 99.8% above the last closing price of $6.97. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $296.1M and an EPS of -$0.14. For the following fiscal year, 12 analysts project revenue of $64.2M and an EPS of -$3.23. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.
Key risks and what to watch
- High cash burn is reflected in negative operating cash flow of -$273.8M in FY2025.
- Analyst estimates forecast an EPS decline to -$3.23 for the fiscal year following FY2026.
- With a beta of 1.81 and a short interest of 9.6% of the float, the stock exhibits elevated volatility.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ARVN AI stock analysis
This page is an AI-written research summary of Arvinas, Inc. (ARVN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ARVN income statement, ARVN balance sheet, ARVN key metrics, ARVN analyst forecast, ARVN chart. See the ARVN stock overview for the latest quote and news.
ARVN AI stock analysis FAQ
What is Arvinas' cash and debt position?
As of June 30, 2026, Arvinas held $567.9M in cash and short-term investments alongside $8.2M in total debt, giving it net cash of $559.7M.
What do analysts expect for ARVN's future earnings?
Analysts estimate an EPS of -$0.14 on revenue of $296.1M for FY2026. For the following fiscal year, estimates project revenue of $64.2M and an EPS of -$3.23.
Does Arvinas pay a dividend?
Arvinas does not pay a dividend. In FY2025, the company deployed capital toward $1.9M in capital expenditures and $91.9M in share buybacks.
How has ARVN stock performed compared to the broader market?
Over the past year, ARVN fell 28.0% compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock is down 91.8% while the index gained 83.0%.